Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Taiwan Liposome Company stock | $7

Learn how to easily invest in Taiwan Liposome Company stock.

Taiwan Liposome Company Ltd is a biotechnology business based in the US. Taiwan Liposome Company shares (TLC) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Taiwan Liposome Company

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TLC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Taiwan Liposome Company stock price (NASDAQ: TLC)

Use our graph to track the performance of TLC stocks over time.

Taiwan Liposome Company shares at a glance

Information last updated 2021-10-18.
Latest market close$7.00
52-week range$4.07 - $7.70
50-day moving average $7.16
200-day moving average $6.37
Wall St. target price$9.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.67

Buy Taiwan Liposome Company shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Taiwan Liposome Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Taiwan Liposome Company price performance over time

Historical closes compared with the close of $7 from 2021-10-06

1 week (2021-10-09) N/A
1 month (2021-09-20) -1.41%
3 months (2021-07-20) 3.70%
6 months (2021-04-20) 20.48%
1 year (2020-10-20) 45.83%
2 years (2019-10-18) 33.33%
3 years (2018-10-16) N/A
5 years (2016-10-16) N/A

Taiwan Liposome Company financials

Revenue TTM $276 million
Gross profit TTM $101.9 million
Return on assets TTM -34.73%
Return on equity TTM -108.77%
Profit margin -283.11%
Book value $4.19
Market capitalisation $302.8 million

TTM: trailing 12 months

Shorting Taiwan Liposome Company shares

There are currently 5,619 Taiwan Liposome Company shares held short by investors – that's known as Taiwan Liposome Company's "short interest". This figure is 79.1% up from 3,138 last month.

There are a few different ways that this level of interest in shorting Taiwan Liposome Company shares can be evaluated.

Taiwan Liposome Company's "short interest ratio" (SIR)

Taiwan Liposome Company's "short interest ratio" (SIR) is the quantity of Taiwan Liposome Company shares currently shorted divided by the average quantity of Taiwan Liposome Company shares traded daily (recently around 13704.87804878). Taiwan Liposome Company's SIR currently stands at 0.41. In other words for every 100,000 Taiwan Liposome Company shares traded daily on the market, roughly 410 shares are currently held short.

However Taiwan Liposome Company's short interest can also be evaluated against the total number of Taiwan Liposome Company shares, or, against the total number of tradable Taiwan Liposome Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Taiwan Liposome Company's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Taiwan Liposome Company shares in existence, roughly 0 shares are currently held short) or 0.0003% of the tradable shares (for every 100,000 tradable Taiwan Liposome Company shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Taiwan Liposome Company.

Find out more about how you can short Taiwan Liposome Company stock.

Taiwan Liposome Company share dividends

We're not expecting Taiwan Liposome Company to pay a dividend over the next 12 months.

Have Taiwan Liposome Company's shares ever split?

Taiwan Liposome Company's shares were split on a 506:503 basis on 9 June 2020. So if you had owned 503 shares the day before before the split, the next day you'd have owned 506 shares. This wouldn't directly have changed the overall worth of your Taiwan Liposome Company shares – just the quantity. However, indirectly, the new 0.6% lower share price could have impacted the market appetite for Taiwan Liposome Company shares which in turn could have impacted Taiwan Liposome Company's share price.

Taiwan Liposome Company share price volatility

Over the last 12 months, Taiwan Liposome Company's shares have ranged in value from as little as $4.07 up to $7.7. A popular way to gauge a stock's volatility is its "beta".

TLC.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Taiwan Liposome Company's is 0.7972. This would suggest that Taiwan Liposome Company's shares are less volatile than average (for this exchange).

Taiwan Liposome Company overview

Taiwan Liposome Company, Ltd. , a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.

Taiwan Liposome Company in the news

There are no recent company news

Frequently asked questions

What percentage of Taiwan Liposome Company is owned by insiders or institutions?
Currently 0.124% of Taiwan Liposome Company shares are held by insiders and 1.757% by institutions.
When does the fiscal year end for Taiwan Liposome Company?
Taiwan Liposome Company's fiscal year ends in December.
Where is Taiwan Liposome Company based?
Taiwan Liposome Company's address is: No. 3 Yuanqu Street, Taipei, Taiwan, 11503
What is Taiwan Liposome Company's ISIN number?
Taiwan Liposome Company's international securities identification number is: US8740381020
What is Taiwan Liposome Company's CUSIP number?
Taiwan Liposome Company's Committee on Uniform Securities Identification Procedures number is: 874038102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site